TAT-AKAP79 (326-336) peptide

TAT-AKAP79 (326-336) peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-YGRKKRRQRRRKSKSEESKRME-OH

H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Ser-Lys-Ser-Glu-Glu-Ser-Lys-Arg-Met-Glu-OH

22

95.13%

C₁₁₇H₂₁₁N₄₉O₃₄S

2880.29

Synthetic

Powder

TAT-AKAP79 (326-336) is amino acids 326–336 of A-kinase anchoring protein 79 (AKAP79), the human anchoring protein, fused to TAT to promote uptake across the cell membrane. AKAP79 (326-336) is the the key region of AKAP79 for interaction with transient receptor potential vanilloid 1 (TRPV1), the thermo-TRP ion channel activated by painful levels of heat, and AKAP79 binding to TRPV1 blocks TRPV1 sensitization. TAT-AKAP79 (326-336) inhibits inflammatory hyperalgesia in mice.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Btesh et al (2014) Mapping the Binding Site of TRPV1 on AKAP79: Implications for Inflammatory Hyperalgesia. J Neurosci. 33(21) 9184 PMID: 23699529

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.